Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Annick Diane Van Den Abbeele, M.D.


This page shows the publications co-authored by Annick Van Den Abbeele and Frank Hodi.
Connection Strength

  1. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8511.
    View in: PubMed
    Score: 0.494
  2. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15.
    View in: PubMed
    Score: 0.166
  3. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
    View in: PubMed
    Score: 0.157
  4. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42.
    View in: PubMed
    Score: 0.151
  5. Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. Cancer Imaging. 2013 Dec 30; 13(4):626-32.
    View in: PubMed
    Score: 0.148
  6. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.143
  7. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
    View in: PubMed
    Score: 0.100
  8. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.